Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Alogliptin Strategy: Treatment Options

This article was originally published in PharmAsia News

Executive Summary

With patent protection for its blockbuster insulin-resistance drug Actos (pioglitazone) set to expire in 2011, Takeda is testing its new Type 2 diabetes candidate, alogliptin, in several therapeutic settings to give physicians confidence the drug will fit into a variety of treatment plans
Advertisement

Related Content

AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Advertisement
UsernamePublicRestriction

Register

SC068671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel